Background There is evidence that trimetazidine, an antiischaemic agent with a direct cytoprotective effect on the myocardium, is effective in stable angina. However, it is not clear whether trimetazidine can improve the mechanical efficiency of chronically dysfunctional myocardium, and whether this potentially beneficial effect can translate into improvements in left ventricular function as well as functional capacity.
Introduction

Trimetazidine
(1-[2,3,4-trimethoxy-benzyl]piperazine dihydrochloride) is a novel antiischaemic compound with a peculiar mechanism of action. Its antiischaemic properties are unrelated to changes in the myocardial oxygen supply-to-demand ratio, as shown by there being no significant effects on heart rate, blood pressure or rate-pressure product either at rest or during dynamic exercise [1] [2] [3] . The cytoprotective effect of trimetazidine is obtained by direct inhibition of mitochondrial longchain 3-ketoacyl coenzyme A thiolase [4] . As a consequence, glucose oxidation in the heart is increased by a shift of energy substrate reference from fatty acid to glucose oxidation. In conditions of ischaemia, the preferential breakdown of glycogen improves energy metabolism, because ATP resynthesis requires less oxygen. Coupled with this effect, trimetazidine decreases the intracellular accumulation of sodium and calcium ions, and protects ventricular cell membranes against the accumulation of hydrogen ions [5] . Both effects on energy metabolism and cellular structural integrity may theoretically translate into cardiac mechanical efficiency.
Although a cytoprotective effect has recently been described in animal as well as human models of acute myocardial ischaemia [6, 7] , it is unclear whether trimetazidine may improve contractility of dysfunctional myocardium adapted to a chronic reduction in blood flow.
The objective of the present investigation was to determine whether trimetazidine improves the contractile response to dobutamine of chronically dysfunctional myocardium in patients with ischaemic cardiomyopathy, and whether this effect can translate into improvements in left ventricular systolic function and functional capacity.
Methods
Forty-four patients with ischaemic cardiomyopathy were enrolled initially. Of these patients, six were subsequently excluded because of a poor acoustic window (four) or poor motivation (two). Thus, 38 patients completed the study. All patients had a prior myocardial infarction and a depressed left ventricular systolic function (Table 1) . Coronary lesion score and collateral score were similar in the two groups. Patients were excluded if they had had a recent acute myocardial infarction (<3 months), had unstable angina, uncontrolled systemic hypertension, complex ventricular arrhythmias, atrial fibrillation, acute heart failure in the last 3 months or renal insufficiency (creatinine d2·5 mg . dl 1 ). The protocol was discussed and approved by the Ethical Committee of the Lancisi Institute. The study was double-blind and placebo-controlled. All patients signed the informed consent. Patients were randomized into two homogeneous groups. Group A (n=19 patients) received trimetazidine at a dose of 20 mg three times daily for 2 months. Group B (n=19 patients) received a placebo during the same period. Patients were asked to report symptoms in a diary. Short-and longacting nitrates were allowed and their dosage was not altered during the study (Table 1) . No patients were taking calcium-antagonists. Patients were visited by a cardiologist at the Lancisi hospital after 1 month and at the end of the protocol. On study entry and at 2 months, all patients underwent a dobutamine stress echocardiographic study and a cardiopulmonary exercise test.
Dobutamine stress echocardiography
Under continuous ECG monitoring, dobutamine was infused into a peripheral antecubital vein at an incremental regimen of 5 g . kg 1 . min 1 every 3 min until a maximum level of 20 g . kg 1 . min 1 was attained. Systolic blood pressure was taken at baseline and at the end of each stage. Nitrates and beta-blockers were withdrawn 2 and 7 days before dobutamine stress testing, respectively. End-points of the study included a new wall motion abnormality, significant ST segment changes (i.e. ST-segment depression or elevation d1 mm or more in two contiguous leads), significant symptoms or arrhythmias or completion of the protocol. A 12-lead ECG recording was taken every minute. Echocardiographic studies were performed with the patients supine in the left lateral position. Twodimensional echo images were continuously acquired from the parasternal long-axis, short axis and apical four-and two-chamber views using a wide-angle mechanical scanner (2·5 MHz, Challenge, ESAOTE, Italy).
Measurements
End-diastole was defined as the frame coinciding with the peak R wave of the QRS complex on the ECG. End systole was defined as the frame at the end of the T wave. Left ventricular end-diastolic volume and endsystolic volume were obtained from the apical four-and two-chamber views using a modified Simpson's rule, from which ejection fraction was automatically calculated as the difference between end-diastolic volume and end-systolic volume normalized to end-diastolic volume. We used a biplane algorithm to calculate left ventricular volumes. A 16-segment model was used for analysis [8] . Each segment was visually graded using a semiquantitative scoring system, where 1=normal, 2=hypokinetic, 3=akinetic and 4=dyskinetic. A regional systolic wall thickening score index was defined as a value falling outside the established 95% CI for each segment of a 
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normal population database from our laboratory [9] . The systolic wall thickening score index was calculated at rest and at each stage of the dobutamine infusion. A 20% reduction in systolic wall thickening represents the 95% CI, ensuring a significant difference between normal and abnormal contractile responses to low-dose dobutamine by two-dimensional echocardiography in our laboratory.
Data analysis
All studies were analysed with an off-line system equipped with digital processing (Panasonic AG 7700). Representative cycles of rest and peak dobutamine dose images in comparable views were digitized and positioned side by side in a quad screen format. The echocardiographic images were evaluated in a blinded manner by two independent, experienced observers, unaware of the clinical picture, who adopted the same assessment criteria. Disagreement between the two observers occurred in 7% of studies. Differences in interpretation were resolved by a third independent cardiologist. Responses to dobutamine were defined as follows: normal response -segments with normal wall thickening at rest with a persistent hyperdynamic response to dobutamine; viable response -an improvement in systolic wall thickening by at least one grade in two adjacent segments with rest asynergy at any stage of dobutamine infusion (i.e. from score 3 at rest to 2 or 1 during infusion); ischaemic response -hypokinesia, akinesia or dyskinesia from normal segments at rest or an initial improvement in wall thickening from an abnormal segment at rest followed by worsening thickening at higher doses of dobutamine infusion (biphasic response). On second examination, an improvement in the contractile response to dobutamine, compared with the initial evaluation, was considered a reduction in systolic wall thickening index by d1 at peak infusion and/or a d20% reduction in systolic wall thickening in at least two adjacent segments.
Cardiopulmonary exercise test
An exercise test was performed for two reasons: to assess patients' functional capacity and ischaemic threshold, and to determine their changes with therapy. Patients pedalled on an electronically braked cycle ergometer until volitional fatigue. Other criteria for stopping exercise were dyspnoea, ischaemic ST-T wave changes, complex ventricular arrhythmias and a reduction in systolic blood pressure of d10 mmHg with increasing work rate. A positive exercise test was defined as either typical angina and 1 mm ST-segment depression (1 mm ST depression) or more, or ST-downsloping d3 mm without anginal pain. Heart rate was continuously monitored and a 12-lead electrocardiogram was recorded at 1-min intervals until recovery. At the same time, blood pressure was measured manually using a brachial sphygmomanometer. After 1 min of rest and 2 min of loadless warm-up, the work rate was automatically increased by 1 W every 3 s in a ramp-like manner. Expired volumes and flows as well as oxygen uptake and carbon dioxide production were measured breath-by-breath on a Sensormedics 2900 Z unit (Yorba Linda, California, U.S.A.). Oxygen uptake at peak (peak VO 2 ) was considered to be the average oxygen uptake during the last 15 s of an exercise session. At 2 months, an improvement in functional capacity was considered to be an increase in peak VO 2 d15% compared with the initial value. This value is 50% above the average difference of two consecutive peak VO 2 values measured in the same individual in our laboratory (7·3 4·5% in 180 subjects).
Statistical analysis
Data were analysed by a commercially available statistical package (SPSS 6.1 for Macintosh). A two-tailed Student's t-test was used for intra-group comparisons. The effects of trimetazidine on metabolic, haemodynamic and echocardiographic variables were analysed by two-way analysis of variance. The Fisher's exact test was used to determine whether the response of the systolic wall thickening index to dobutamine predicted the improvement in peak VO 2 after trimetazidine. Statistical significance was assumed for P<0·05. Data are expressed as mean SD.
Results
Dobutamine stress echocardiography
Thirty-eight patients completed the protocol. On study entry, there were no differences in heart rate, systolic blood pressure at rest and peak dobutamine infusion between the two groups ( Table 2) . At rest, all patients had a similar percentage of left ventricular myocardial segments with wall motion and systolic thickening abnormalities, and a similar left ventricular ejection fraction and systolic wall thickening score index ( Table  2 ). The contractile response to dobutamine infusion was not significantly different between the two groups. In group A, of 19 patients, 13 had a viable response and six had an ischaemic response to dobutamine infusion. In group B, 14 and five patients, respectively, had a viable and an ischaemic response to dobutamine. Minor complications occurred during dobutamine infusion. Eight patients had isolated premature contractions at peak infusion, four had hypotension at the end of the infusion, and seven had angina.
During the period of treatment, there were no adverse events in either group and no patient stopped or modified the prescribed regimen. At 2 months, no significant changes in heart rate or systolic blood pressure responses to dobutamine were observed in the two groups (Table 2 ). In control patients there were no changes in the contractile response to dobutamine compared with initial studies. In patients receiving trimetazidine, 17 had a viable response and two an ischaemic response. Fourteen of the 17 viable responses were evident in noninfarcted areas. In more detail, of dysfunctional segments located in non-infarct areas, 69 showed an improved contractile response to dobutamine infusion compared with initial studies. Of them, 59 were hypokinetic and 10 akinetic at rest (before dobutamine infusion). Patients with a viable response had a greater ejection fraction at peak dobutamine than patients with an ischaemic response (45 2·5% vs 39 4%, P<0·001). No changes in left ventricular function and contractility were observed in the control group. Table 3 shows the contractile responses of dysfunctional myocardial segments. In the initial evaluation, in the trimetazidine group, of the abnormal segments in which contractility improved during dobutamine infusion (76 of 189), 54 were hypokinetic and 22 akinetic at rest. The control group had a similar proportion of segments with a contractile response (71 of 176). At 2 months, however, only treated patients demonstrated improved contractility in 99 out of 179 segments (+30·3% vs study entry, P=0·005 vs controls) (Fig. 1) . This effect can explain the improvements in the systolic wall thickening score index (20·8%; P<0·001 vs controls) and ejection fraction (14%, P<0·001) at peak dobutamine. In patients treated with trimetazidine, an improvement in systolic wall thickening, compared with the initial study, was observed in 14 patients. This improvement was evident during the initial 3 min of dobutamine infusion in patients with a viable response.
Cardiopulmonary exercise test
On the initial exercise stress test, an ischaemic threshold was identified in five patients in each group (group A: 85 16 W; group B: 89 16 W; P ns).
At 2 months, peak VO 2 significantly improved in treated patients (from 16·4 1·4 ml . kg 1 . min 1 to 18·9 1·7 ml . kg 1 . min 1 , P=0·001 vs controls), despite no change in resting or peak heart rate or blood pressure in either group. As shown in Fig. 2 , of the 14 
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patients treated with trimetazidine in whom the systolic wall thickening score index improved, 11 had a concomitant increase in peak VO 2 , while none of the five patients with no improvement in contractility showed an increase in peak VO 2 . By contrast, among the control patients, 17 of 18 with no contractile improvement also had no change in peak VO 2 . There was no difference in the magnitude of the increase in peak VO 2 between patients with a viable response to dobutamine and patients with an ischaemic response on the initial evaluation. An ischaemic threshold was identified in three patients receiving trimetazidine and was significantly higher than baseline (113 6 W; P<0·05). No change in the ischaemic threshold from baseline was observed in the control group (86 15 W, P ns vs initial evaluation).
As shown in Table 4 , patients with an increased peak VO 2 at 2 months had a similar resting ejection fraction, coronary lesion score and NYHA functional class to the subgroup of patients with unchanged peak VO 2 , but greater improvements in peak VO 2 , ejection fraction at peak dobutamine, end-systolic volume and systolic thickening at 2 months.
Discussion
The results of the present investigation show that trimetazidine improves the contractile response of chronically dysfunctional myocardium to dobutamine in patients with coronary artery disease and depressed left ventricular function without adverse events. This effect translated into a significant increase in left ventricular ejection fraction at rest as well as at peak dobutamine infusion, and was not associated with haemodynamic changes. Peak VO 2 was also increased in 16 of the 19 patients receiving the drug. By contrast, after 2 months, patients receiving placebo had neither changes in the inotropic response of dysfunctional myocardium to dobutamine nor improvement in functional capacity.
Trimetazidine is representative of a new group of pharmaceutical compounds with a myocardial antiischaemic effect achieved independently of changes in Delta VO 2 =difference between peak VO 2 at 2 months and peak VO 2 at baseline; Peak=at peak dobutamine infusion; SWTI=systolic wall thickening index.
the oxygen supply-to-demand ratio. Unlike other classical antiischaemic drugs, trimetazidine neither reduces oxygen consumption nor increases oxygen supply, since no significant changes in heart rate, blood pressure or the rate-pressure product have been observed in resting condition or during exercise [1] [2] [3] . The antiischaemic effect of trimetazidine is obtained at a cellular level by shifting the energy substrate reference from fatty acid oxidation to glucose oxidation [4] . Since more ATP is produced per oxygen consumed when glycogen is a substrate, compared with fatty acids, less oxygen is required to do a given amount of work. In experimental studies, trimetazidine exerts a cardioprotective effect for in vitro models of myocardial ischaemia because of a more rapid restoration of phosphorylation processes [10] , protection of cardiac cells against the accumulation of protons [6] , and prevention of the intracellular accumulation of sodium and calcium ions [5] . Recently, trimetazidine improved resting as well as dobutamine-induced ischaemic dysfunction in patients with coronary artery disease and normal left ventricular systolic function [7] . In this study, patients were blindly and randomly assigned to a 15-day treatment with either oral trimetazidine (20 mg three times daily) or placebo. They were then crossed over to the other regimen for a further 15 days. However, the authors did not analyse the response of left ventricular ejection fraction to dobutamine. Moreover, they used higher doses of dobutamine than those of the present investigation, because their objective was different. They aimed to determine the antiischaemic effect of trimetazidine in conditions of myocardial ischaemia acutely triggered by high doses of dobutamine. Dobutamine is able to increase contractility fourfold more than heart rate at low doses (c20 g . kg 1 . min 1 ). At doses >30 g . kg 1 . min 1 the chronotropic stimulation increases to levels comparable to those obtained with intense exercise, and myocardial ischaemia may develop.
We used a different human model of ischaemic heart disease and a different protocol of dobutamine infusion. We studied patients with chronic left ventricular dysfunction and multivessel coronary artery disease who had had no angina in the last 3 months. This scenario represents a complex pathophysiological picture, where different amounts of myocardial necrotic cells are combined with chronically hibernating and stunned cells. Myocardial cells adapted to chronic reduction in blood flow have structural and metabolic alterations. ATP resynthesis is reduced, glycogen accumulates and contractile material is lost. Positron emission tomography studies have demonstrated that basal regional myocardial perfusion in these cells is sometimes near normal or moderately reduced, while contractility is disproportionately depressed [11] . Abnormally contracting segments have a reduced coronary flow reserve and their contractile reserve can be recruited during appropriate inotropic stimulation. We used lower doses of dobutamine, because we focused on the contractile response of the dysfunctional myocardium, which can be determined with doses below 20 g . kg 1 . min 1 . It has been reported that more than 90% of dysfunctional myocardial segments respond to doses of dobutamine <10 g . kg 1 . min 1 [12] . In the setting of multivessel coronary artery disease, the infusion of higher doses of dobutamine may provoke ischaemic rather than contractile responses, and untoward cardiac events may develop.
The improvement in the contractile response of dysfunctional myocardium to dobutamine after trimetazidine can be explained partly by the effects of the drug, which can help to maintain the integrity of cell membranes as well as mitochondrial structure and function [13] . In the isolated rat heart, trimetazidine significantly limits the decrease in mechanical performance under conditions of hypoxia [10] . Since no changes in rate-pressure product were observed at any stage of dobutamine infusion or during work rate increases in patients taking trimetazidine, it is unlikely that the improved contractility was due to a greater oxygen supply to the dysfunctional myocardium. It is more likely that an increase in glucose oxidation in chronic low flow states can increase glycolytic ATP resynthesis and improve contractility [14] . The upregulation in contractile function after trimetazidine suggests that chronic post-ischaemic stunned cells normalize their metabolism and function. It is also possible that chronically hibernated cells can improve their energy metabolism with trimetazidine. This effect can translate into mechanical efficiency and contribute to reduce left ventricular dysfunction. We found a significant improvement in left ventricular contractility in dysfunctional segments located in non-infarcted areas served by a severely stenotic artery, and in these hibernation is likely to occur.
Left ventricular ejection fraction also improved at rest and during dobutamine infusion in patients taking trimetazidine. This result is in agreement with a previous report showing a 9·3% improvement in radionuclide ejection fraction after a 6-month treatment with trimetazidine at usual doses (20 mg three times daily) [15] . The improvement in contractility induced by trimetazidine can have potential therapeutic and prognostic implications. An important effect may be an increase in stroke volume during daily submaximal physical activities that can allow a more active lifestyle and improve functional capacity and, possibly, quality of life. Peak VO 2 , an objective and reproducible index of functional capacity, was increased in 16 out of 19 patients receiving trimetazidine, and in 11 of them there was a concordant improvement in systolic wall thickening (Fig. 2) . Moreover, as suggested in Table 3 , trimetazidine, by increasing the number of significant viable segments, may render more patients amenable to myocardial revascularization.
Limitations
Post-necrotic mechanical dysfunction may be related to hibernated and/or stunned myocardium. Since we
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did not measure myocardial blood flow, we cannot determine the specific effect of trimetazidine in each condition. Moreover, the small number of patients studied could have over-estimated the improvement in contractility induced by trimetazidine. Since the doses of dobutamine used in both initial and follow-up studies were identical, the observed improvement in the contractile response to dobutamine and ejection fraction is probably due to the effect of trimetazidine itself.
In conclusion, trimetazidine improves the contractile response of chronically dysfunctional myocardium to dobutamine both at rest and at peak infusion. This favourable effect translated into significant improvements in left ventricular function and functional capacity, and was not associated with any adverse events. The absence of haemodynamic changes in patients consuming trimetazidine supports the hypothesis that the drug exerts a direct cytoprotective effect on myocardial cells. If confirmed in larger studies, these results could have potential therapeutic and prognostic implications.
